EP0512755B1 - Piperazine derivatives - Google Patents
Piperazine derivatives Download PDFInfo
- Publication number
- EP0512755B1 EP0512755B1 EP92303918A EP92303918A EP0512755B1 EP 0512755 B1 EP0512755 B1 EP 0512755B1 EP 92303918 A EP92303918 A EP 92303918A EP 92303918 A EP92303918 A EP 92303918A EP 0512755 B1 EP0512755 B1 EP 0512755B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- piperazinyl
- ethyl
- methoxyphenyl
- cyclohexanecarboxamide
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 CC1(*)CN(**)CCN(C)C1 Chemical compound CC1(*)CN(**)CCN(C)C1 0.000 description 6
- UNWXGPMJYZFHEO-UHFFFAOYSA-N CCC(C)(C)CN(C)CCNNN Chemical compound CCC(C)(C)CN(C)CCNNN UNWXGPMJYZFHEO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- This invention relates to piperazine derivatives, to processes for their preparation, to their use and to pharmaceutical compositions containing them.
- the novel compounds act on the central nervous system by binding to 5-HT receptors (as more fully explained below) and hence can be used as medicaments for treating humans and other mammals.
- EP-A-0372657 discloses a group of 1,4-disubstituted piperazine derivatives which are stated to have psychotropic properties.
- novel compounds of the invention are those of the general formula and the pharmaceutically acceptable acid addition salts thereof.
- A is an alkylene chain of 2 to 4 carbon atoms optionally substituted by one or more lower alkyl groups, Z is oxygen or sulphur, R is hydrogen or lower alkyl, R1 is a mono or bicyclic aryl or heteroaryl radical, R2 is a mono or bicyclic heteroaryl radical and R3 is hydrogen, lower alkyl, cycloalkyl, cycloalkenyl, cycloalkyl(lower)alkyl, aryl, aryl(lower)alkyl, heteroaryl, heteroaryl(lower)alkyl, a group of formula -NR4R5 [where R4 is hydrogen, lower alkyl, aryl or aryl(lower)alkyl and R5 is hydrogen, lower alkyl, -CO(lower)alkyl, aryl, COaryl, aryl(lower)alkyl, cycloalkyl or cycloalkyl-(lower)alkyl or
- lower as used herein means that the radical referred to contains 1 to 6 carbon atoms. Preferably such radicals contain 1 to 4 carbon atoms. Examples of “lower alkyl” radicals are methyl, ethyl, propyl, isopropyl, butyl, tert.-butyl, pentyl and isopentyl.
- cycloalkyl groups are cyclopentyl, cyclohexyl and cycloheptyl. A preferred example is cyclohexyl.
- Cycloalkyl groups include bicyclic, tricyclic and tetracyclic groups, eg adamantyl. Preferably the cycloalkyl group contains 3 to 12 carbon atoms.
- aryl means an aromatic radical having 6 to 12 carbon atoms (eg phenyl or naphthyl) which optionally may be substituted by one or more substituents.
- Preferred substituents are lower alkyl, lower alkoxy (eg methoxy, ethoxy, propoxy, butoxy), halogen, halo(lower)alkyl (eg trifluoromethyl), nitro, nitrile, amido, (lower)alkoxycarbonyl, amino, (lower)alkylamino or di(lower)alkylamino substituents.
- Two substituents on the aromatic ring may be connected together to form another ring system.
- R1 may be an optionally substituted tetrahydronaphthyl radical or a bicyclic oxygen-containing radical of the formula wherein the heterocyclic ring containing the oxygen atom contains a total of 5 to 7 ring members, said heterocyclic ring being saturated or unsaturated, being optionally substituted and optionally containing one or more hetero ring members (eg -O-, NR7 - where R7 is hydrogen or lower alkyl, -S- or -SO2-) in addition to the oxygen atom illustrated and wherein R8 represents hydrogen or one or more same or different substituents selected from lower alkyl, halogen, oxo, hydroxy, (lower)alkoxy, hydroxy(lower)alkyl, (lower)alkoxy(lower alkyl), lower alkanoyloxy(lower alkyl), (lower)alkylcarbonyl, (lower)alkylcarbonyl(lower)alkyl, amino, (lower)alkyla
- Preferred examples of a bicyclic oxygen-containing radical are those of the formulae where R8 is as defined above, R9 has the definition of R8 given above and X is -CO-, -S-, or -NR7- where R7 is hydrogen or lower alkyl.
- R1 is an aryl radical it is preferably a phenyl radical containing a substituent in the ortho position.
- a preferred example of R1 is o-(lower)alkoxyphenyl eg o-methoxyphenyl.
- R1 can also be, for example a 1-naphthyl radical optionally substituted in the 2 or 7 positions by, for example, (lower)alkoxy.
- aryl(lower)alkyl are benzyl and phenethyl in which the phenyl rings may be substituted by substituents as given above.
- heteroaryl refers to an aromatic radical containing one or more hetero atoms (eg oxygen, nitrogen, sulphur) and which may be optionally substituted by one or more substituents. Examples of suitable substituents are given above in connection with “aryl” radicals.
- the heteroaryl radical may, for example, contain up to 10 ring atoms.
- the heteroaryl radical is a monocyclic radical containing 5 to 7 ring atoms.
- the hetero ring contains a nitrogen hetero atom with or without one or more further hetero atoms.
- R1 is a heteroaryl radical it is preferably an optionally substituted pyrimidyl (particularly 2-pyrimidyl), isoquinolinyl (particularly 1-isoquinolinyl) or 1,2-benzisothiazolyl radical.
- R2 is a bicyclic heteroaryl radical both rings of the radical may contain hetero ring atoms or only one ring may contain a hetero atom or atoms. In the latter instance the radical R2 is connected to the rest of the molecule of formula (I) via the ring containing the hetero atom(s).
- heteroaryl radical R2 examples include monocyclic radicals containing one hetero atom, eg optionally substituted pyridyl (particularly 2-pyridyl), monocyclic radicals containing two hetero atoms, eg thiazolyl (particularly 2-thiazolyl) and bicyclic radicals containing one or two hetero atoms eg quinolinyl or isoquinolinyl (particularly 2-quinolinyl).
- R4 and R5 together with the nitrogen atom to which they are both attached represent a saturated heterocyclic ring this may be, for example, azetidino, pyrrolidino, piperidino, hexahydroazepino, morpholino or piperazino which may be optionally substituted by, for example, lower alkyl, aryl or aryl(lower)alkyl.
- Preferred compounds have the following substituents either independently or in combination:-
- One method of preparing the compounds of the invention comprises acylating an amine of formula (where A, R, R1 and R2 have the meanings given above) with an acid of formula R3CZOH (III) (where Z and R3 is as defined above) or with an acylating derivative thereof.
- Z is preferably oxygen.
- acylating derivatives include the acid halides (eg acid chlorides), azides, anhydrides, imidazolides (eg obtained from carbonyldiimidazole), activated esters or O-acyl ureas obtained from a carbodiimide such as a dialkylcarbodiimide particularly cyclohexylcarbodiimide.
- R3 is -NR4R5 are urea or thiourea derivatives and may be prepared by reacting an amine of formula (II) with the appropriate isocyanate or isothiocyanate (including an appropriate acylisocyanate or acylisothiocyanate).
- Ureas in which R5 is -CO(lower)alkyl or -CO aryl may also be prepared by acylating the corresponding urea or thiourea in which R5 is hydrogen.
- the starting amine of formula (II) may be prepared by a process such as that exemplified below: (where R, R1, R2 and A are as defined above, Hal is halo, particularly chloro or bromo and A' is an alkylene chain of 1 to 3 carbon atoms optionally substituted by one or more lower alkyl groups).
- the reduction may be carried out with, for example, a boron reducing agent eg borane-dimethyl sulphide or a complex metal hydride, eg lithium aluminium hydride.
- amines of formula (II) are novel.
- a particularly preferred novel amine, which is provided by the present invention is 1-(2-methoxyphenyl)-4-[2-(2-pyridinylamino)ethyl]-piperazine.
- a further method of preparing the compounds of the invention comprises alkylating an amide or thioamide of formula (IV) with an alkylating agent providing the group
- the alkylating agent may be, for example, a compound of formula where A, R and R1 are as defined above and X is a leaving group such as halogen or an alkyl - or aryl-sulphonyloxy group. Z is preferably oxygen.
- a further method of preparing the compounds of the invention comprises alkylating a compound of formula with a compound of formula X-A NR2.CZ.R3 (V) (where A, R, R1, R2, R3, Z and X are as defined above). Z is preferably oxygen.
- the starting compound of formula (V) may, for example, be prepared as exemplified below X-A-Br + NHR2CZR3 (V)
- a further method of preparing the compounds of the invention comprises heteroarylating a compound of formula with a compound providing the heteroaryl group R2.
- the compound of formula (VI) may be reacted with a fluoro compound of formula R2F eg in the presence of a strong non-nucleophilic base (eg lithium diisopropylamide).
- R1 is a group that is activated towards nucleophilic substitution
- the compounds of the invention may be prepared by a further method which comprises reacting the appropriate fluoro compound of formula R1F with a piperazine compound of formula
- Compounds of the invention in which Z is sulphur may be prepared by sulphurisation of compounds of the invention where Z is oxygen.
- the compounds where Z is oxygen may, for example, be reacted with a sulphurising agent such as a mixture of phosphorus pentasulphide and potassium sulphide.
- the processes described above may be carried out to give a compound of the invention in the form of a free base or as an acid addition salt. If the compound of the invention is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid addition salt. Conversely, if the product of the process is a free base an acid addition salt, particularly a pharmaceutically acceptable acid addition salt, may be obtained by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds.
- acid addition salts are those formed from inorganic and organic acids, such as sulphuric, hydrochloric, hydrobromic, phosphoric, tartaric, fumaric, maleic, citric, acetic, formic, methanesulphonic, p-toluenesulphonic, oxalic and succinic acids.
- the compounds of the invention may contain one or more asymmetric carbon atoms, so that some compounds can exist in different steroisomeric forms.
- the compounds can be, for example, racemates or optically active forms.
- the optically active forms can be obtained by resolution of the racemates or by asymmetric synthesis.
- the compounds of the present invention possess pharmacological activity. In particular, they act on the central nervous system by binding to 5-HT receptors. In pharmacological testing it has been shown that the compounds particularly bind to receptors of the 5-HT 1A type. In general, the compounds selectively bind to receptors of the 5-HT 1A type to a much greater extent than they bind to other receptors such as ⁇ 1 and D2 receptors. Many exhibit activity as 5-HT 1A antagonists in pharmacological testing.
- the compounds of the invention can be used for the treatment of CNS disorders, such as anxiety in mammals, particularly humans. They may also be used as antidepressants, hypotensives and as agents for regulating the sleep/wake cycle, feeding behaviour and/or sexual function.
- the compounds of the invention were tested for 5-HT 1A receptor binding activity in rat hippocampal membrane homogenate by the method of B S Alexander and M D Wood, J Pharm Pharmacol, 1988, 40 , 888-891.
- the compounds are tested for 5-HT 1A receptor antagonism activity in a test involving the antagonism of 5-carboxamidotryptamine in the guinea-pig ileum in vitro (based upon the procedure of Fozard et al, Br J Pharmac, 1985, 86 , 601P).
- the results for representative compounds of the invention are given below.
- the compound of Example 3 had a pA2 of 8.7 and that of Example 4 had a pA2 of 7.8 and that of Example 17 had a PA2 of 9.8.
- the invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound or a pharmaceutically acceptable acid addition salt thereof in association with a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier Any suitable carrier known in the art can be used to prepare the pharmaceutical composition.
- the carrier is generally a solid or liquid or a mixture of a solid or liquid.
- Solid form compositions include powders, granules, tablets, capsules (eg hard and soft gelatine capsules), suppositories and pessaries.
- a solid carrier can be, for example, one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, fillers, glidants, compression aides, binders or tablet-disintegrating agents; it can also be an encapsulating material.
- the carrier is a finely divided solid which is in admixture with the finely divided active ingredient.
- the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain up to 99%, eg from 0.03 to 99%, preferably 1 to 80% of the active ingredient.
- Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
- composition is intended to include the formulation of an active ingredient with encapsulating material as carrier to give a capsule in which the active ingredient (with or without other carriers) is surrounded by the carrier, which is thus in association with it. Similarly cachets are included.
- Liquid form compositions include, for example, solutions, suspensions, emulsions, syrups, elixirs and pressurised compositions.
- the active ingredient for example, can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats.
- the liquid carrier can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilisers or osmo-regulators.
- liquid carriers for oral and parenteral administration include water (particularly containing additives as above, eg cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols, eg glycerol and glycols) and their derivatives, and oils (eg fractionated coconut oil and arachis oil).
- the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate.
- Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.
- Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. When the compound is orally active it can be administered orally either in liquid or solid composition form.
- the pharmaceutical composition is in unit dosage form, eg as tablets or capsules.
- the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient;
- the unit dosage forms can be packaged composition, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquid.
- the unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
- the quantity of the active ingredient in unit dose of composition may be varied or adjusted from 0.5 mg or less to 750 mg or more, according to the particular need and the activity of the active ingredient.
- Examples 1,2,7,9,10,12-16,18,19,21-29,32 and 34-45 illustrate the preparation of intermediates and these intermediates, apart from the intermediate of Example 2, are not claimed in the present specification.
- the compound of Example 2 is provided by the present invention.
- Benzoyl chloride (1.69g, 12 mmol) was added cautiously to a stirred solution of Example 2 free base (1.94g, 6 mmol) and di-isopropylethylamine (2.2 ml, 14 mmol) in dichloromethane (20 ml). The mixture was stirred under Ar for 24 h, evaporated in vacuo , and the brown oil dissolved in water (50 ml). The solution was acidified with 2 N -HCl, washed with dichloromethane (3 x 50 ml), basified with 2 N -NaOH, and extracted with dichloromethane (3 x 75 ml).
- 1,2-Dibromoethane (12.0 g, 0.064 mol), potassium carbonate (17.6 g, 0.127 mol) and tetra-n-butyl ammonium bromide (1.37 g, 0.0043 mol) were added to a stirred solution of 3-nitrocatechol (6.59 g, 0.043 mol) in toluene (210 ml).
- the solution was heated at reflux with azeotropic removal of water for 23 h, cooled to room temperature, washed with 2 N sodium hydroxide solution (150 ml), dried (Na2SO4), and evaporated in vacuo to give an orange oil. Purification by column chromatography (silica; ether) gave the product (2.55 g), m.p. 55-59°C.
- Example 27 The product of Example 27 (3.9 g, 16 mmol) and 2-chloropyridine (1.82 g, 16 mmol) were heated at 160°C in a sealed vessel for 6 h. After cooling, the residue was taken up into CH2Cl2 (50 ml) washed with aqueous NaOH (3 x 50 ml), dried (MgSO4) and evaporated in vacuo . The residue was purified by chromatography [alumina; ethyl acetate - toluene (1:4)] to give the product (0.7 g) as a brown oil.
- Example 2 A suspension of the product of Example 2 (3.12 g, 10 mmol) in DMSO (50 ml) was added to KH, 35 wt. % dispersion in mineral oil (1 g, 8.7 mmol) under Ar. After 1 h, cyclohexylisothiocyanate (1.41 g, 10 mmol) was added and the mixture was stirred at 80°C for 16 h, cooled to room temperature, and poured onto 2 N -HCl (500 ml). The mixture was washed with ethyl acetate (3 x 200 ml), basified with NaOH, and extracted with ethyl acetate (3 x 100 ml).
- Example 2 The product of Example 2 (5.25 g, 16.8 mmol) in DMF (40 ml) was treated with potassium tert -butoxide (4.53 g, 40 mmol) under Ar, treated with propanethiol (3.14 g, 41.3 mmol), stirred at 100°C for 18 h, cooled to room temperature, and poured onto water (200 ml). The mixture was extracted with ethyl acetate (3 x 80 ml) and the organic phases combined, washed with water (40 ml), dried (MgSO4) and evaporated in vacuo . Purification by chromatography [alumina; hexane-ethyl acetate (1:1)] gave the product as an oil (2.79 g). The trihydrochloride salt was a colourless solid, m.p. 260-265°C.
Abstract
Description
- This invention relates to piperazine derivatives, to processes for their preparation, to their use and to pharmaceutical compositions containing them. The novel compounds act on the central nervous system by binding to 5-HT receptors (as more fully explained below) and hence can be used as medicaments for treating humans and other mammals.
- EP-A-0372657 discloses a group of 1,4-disubstituted piperazine derivatives which are stated to have psychotropic properties.
-
- In formula (I)
A is an alkylene chain of 2 to 4 carbon atoms optionally substituted by one or more lower alkyl groups,
Z is oxygen or sulphur,
R is hydrogen or lower alkyl,
R¹ is a mono or bicyclic aryl or heteroaryl radical,
R² is a mono or bicyclic heteroaryl radical
and R³ is hydrogen, lower alkyl, cycloalkyl, cycloalkenyl, cycloalkyl(lower)alkyl, aryl, aryl(lower)alkyl, heteroaryl, heteroaryl(lower)alkyl, a group of formula -NR⁴R⁵ [where R⁴ is hydrogen, lower alkyl, aryl or aryl(lower)alkyl and R⁵ is hydrogen, lower alkyl, -CO(lower)alkyl, aryl, COaryl, aryl(lower)alkyl, cycloalkyl or cycloalkyl-(lower)alkyl or R⁴ and R⁵ together with the nitrogen atom to which they are both attached represent a saturated heterocyclic ring which may contain a further hetero atom] or a group of formula OR⁶ [where R⁶ is lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, aryl, aryl(lower)alkyl, heteroaryl or heteroaryl(lower)alkyl]. - The term "lower" as used herein means that the radical referred to contains 1 to 6 carbon atoms. Preferably such radicals contain 1 to 4 carbon atoms. Examples of "lower alkyl" radicals are methyl, ethyl, propyl, isopropyl, butyl, tert.-butyl, pentyl and isopentyl.
- Examples of cycloalkyl groups are cyclopentyl, cyclohexyl and cycloheptyl. A preferred example is cyclohexyl. Cycloalkyl groups include bicyclic, tricyclic and tetracyclic groups, eg adamantyl. Preferably the cycloalkyl group contains 3 to 12 carbon atoms.
- When used herein "aryl" means an aromatic radical having 6 to 12 carbon atoms (eg phenyl or naphthyl) which optionally may be substituted by one or more substituents. Preferred substituents are lower alkyl, lower alkoxy (eg methoxy, ethoxy, propoxy, butoxy), halogen, halo(lower)alkyl (eg trifluoromethyl), nitro, nitrile, amido, (lower)alkoxycarbonyl, amino, (lower)alkylamino or di(lower)alkylamino substituents. Two substituents on the aromatic ring may be connected together to form another ring system. For example R¹ may be an optionally substituted tetrahydronaphthyl radical or a bicyclic oxygen-containing radical of the formula
wherein the heterocyclic ring containing the oxygen atom contains a total of 5 to 7 ring members, said heterocyclic ring being saturated or unsaturated, being optionally substituted and optionally containing one or more hetero ring members (eg -O-, NR⁷ - where R⁷ is hydrogen or lower alkyl, -S- or -SO₂-) in addition to the oxygen atom illustrated and wherein R⁸ represents hydrogen or one or more same or different substituents selected from lower alkyl, halogen, oxo, hydroxy, (lower)alkoxy, hydroxy(lower)alkyl, (lower)alkoxy(lower alkyl), lower alkanoyloxy(lower alkyl), (lower)alkylcarbonyl, (lower)alkylcarbonyl(lower)alkyl, amino, (lower)alkylamino or di(lower)alkylamino. -
- When R¹ is an aryl radical it is preferably a phenyl radical containing a substituent in the ortho position. A preferred example of R¹ is o-(lower)alkoxyphenyl eg o-methoxyphenyl. R¹ can also be, for example a 1-naphthyl radical optionally substituted in the 2 or 7 positions by, for example, (lower)alkoxy.
- Preferred examples of aryl(lower)alkyl are benzyl and phenethyl in which the phenyl rings may be substituted by substituents as given above.
- The term "heteroaryl" refers to an aromatic radical containing one or more hetero atoms (eg oxygen, nitrogen, sulphur) and which may be optionally substituted by one or more substituents. Examples of suitable substituents are given above in connection with "aryl" radicals. The heteroaryl radical may, for example, contain up to 10 ring atoms. Preferably the heteroaryl radical is a monocyclic radical containing 5 to 7 ring atoms. Preferably the hetero ring contains a nitrogen hetero atom with or without one or more further hetero atoms. When R¹ is a heteroaryl radical it is preferably an optionally substituted pyrimidyl (particularly 2-pyrimidyl), isoquinolinyl (particularly 1-isoquinolinyl) or 1,2-benzisothiazolyl radical. When R² is a bicyclic heteroaryl radical both rings of the radical may contain hetero ring atoms or only one ring may contain a hetero atom or atoms. In the latter instance the radical R² is connected to the rest of the molecule of formula (I) via the ring containing the hetero atom(s).
- Examples of the heteroaryl radical R² include monocyclic radicals containing one hetero atom, eg optionally substituted pyridyl (particularly 2-pyridyl), monocyclic radicals containing two hetero atoms, eg thiazolyl (particularly 2-thiazolyl) and bicyclic radicals containing one or two hetero atoms eg quinolinyl or isoquinolinyl (particularly 2-quinolinyl).
- When R⁴ and R⁵ together with the nitrogen atom to which they are both attached represent a saturated heterocyclic ring this may be, for example, azetidino, pyrrolidino, piperidino, hexahydroazepino, morpholino or piperazino which may be optionally substituted by, for example, lower alkyl, aryl or aryl(lower)alkyl.
- Preferred compounds have the following substituents either independently or in combination:-
- (a) A is -(CH₂)₂-, -(CH₂)₃-, -(CH₂)₄- or -CH(CH₃).CH₂-
- (b) R is hydrogen
- (c) R¹ is o-methoxyphenyl, o-isopropylphenyl, 4-fluoro-2-methoxyphenyl, 2,3-dihydro[1,4]benzodioxan-5-yl), pyrimid-2-yl, 1-naphthyl,3-(1,2-benzisothiazolyl), 1-(7-methoxynapthyl) or 1-(5,6,7,8)-tetrahydronaphthyl
- (d) R² is pyrid-2-yl, quinolin-2-yl or thiazol-2-yl
- (e) R³ is lower alkyl (eg methyl or t-butyl), cycloalkyl (eg cyclohexyl), cycloalkenyl (eg cyclohexenyl), phenyl, piperidino, adamantyl, or -NHcycloalkyl (eg -NHcyclohexyl)
- (f) Z is oxygen
- One method of preparing the compounds of the invention comprises acylating an amine of formula
(where A, R, R¹ and R² have the meanings given above) with an acid of formula
R³CZOH (III)
(where Z and R³ is as defined above) or with an acylating derivative thereof. Z is preferably oxygen. Examples of acylating derivatives include the acid halides (eg acid chlorides), azides, anhydrides, imidazolides (eg obtained from carbonyldiimidazole), activated esters or O-acyl ureas obtained from a carbodiimide such as a dialkylcarbodiimide particularly cyclohexylcarbodiimide. - Compounds in which R³ is -NR⁴R⁵ are urea or thiourea derivatives and may be prepared by reacting an amine of formula (II) with the appropriate isocyanate or isothiocyanate (including an appropriate acylisocyanate or acylisothiocyanate). Ureas in which R⁵ is -CO(lower)alkyl or -CO aryl may also be prepared by acylating the corresponding urea or thiourea in which R⁵ is hydrogen.
- The starting amine of formula (II) may be prepared by a process such as that exemplified below:
(where R, R¹, R² and A are as defined above, Hal is halo, particularly chloro or bromo and A' is an alkylene chain of 1 to 3 carbon atoms optionally substituted by one or more lower alkyl groups). The reduction may be carried out with, for example, a boron reducing agent eg borane-dimethyl sulphide or a complex metal hydride, eg lithium aluminium hydride. - Some of the amines of formula (II) are novel. A particularly preferred novel amine, which is provided by the present invention is 1-(2-methoxyphenyl)-4-[2-(2-pyridinylamino)ethyl]-piperazine.
- A further method of preparing the compounds of the invention comprises alkylating an amide or thioamide of formula (IV)
with an alkylating agent providing the group
The alkylating agent may be, for example, a compound of formula
where A, R and R¹ are as defined above and X is a leaving group such as halogen or an alkyl - or aryl-sulphonyloxy group. Z is preferably oxygen. - A further method of preparing the compounds of the invention comprises alkylating a compound of formula
with a compound of formula
X-A NR².CZ.R³ (V)
(where A, R, R¹, R², R³, Z and X are as defined above). Z is preferably oxygen. The starting compound of formula (V) may, for example, be prepared as exemplified below
X-A-Br + NHR²CZR³ (V)
A further method of preparing the compounds of the invention comprises heteroarylating a compound of formula
with a compound providing the heteroaryl group R². For example the compound of formula (VI) may be reacted with a fluoro compound of formula R²F eg in the presence of a strong non-nucleophilic base (eg lithium diisopropylamide). - Where R¹ is a group that is activated towards nucleophilic substitution the compounds of the invention may be prepared by a further method which comprises reacting the appropriate fluoro compound of formula R¹F with a piperazine compound of formula
Compounds of the invention in which Z is sulphur may be prepared by sulphurisation of compounds of the invention where Z is oxygen. The compounds where Z is oxygen may, for example, be reacted with a sulphurising agent such as a mixture of phosphorus pentasulphide and potassium sulphide. - The processes described above may be carried out to give a compound of the invention in the form of a free base or as an acid addition salt. If the compound of the invention is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid addition salt. Conversely, if the product of the process is a free base an acid addition salt, particularly a pharmaceutically acceptable acid addition salt, may be obtained by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds.
- Examples of acid addition salts are those formed from inorganic and organic acids, such as sulphuric, hydrochloric, hydrobromic, phosphoric, tartaric, fumaric, maleic, citric, acetic, formic, methanesulphonic, p-toluenesulphonic, oxalic and succinic acids.
- The compounds of the invention may contain one or more asymmetric carbon atoms, so that some compounds can exist in different steroisomeric forms. The compounds can be, for example, racemates or optically active forms. The optically active forms can be obtained by resolution of the racemates or by asymmetric synthesis.
- The compounds of the present invention possess pharmacological activity. In particular, they act on the central nervous system by binding to 5-HT receptors. In pharmacological testing it has been shown that the compounds particularly bind to receptors of the 5-HT1A type. In general, the compounds selectively bind to receptors of the 5-HT1A type to a much greater extent than they bind to other receptors such as α₁ and D₂ receptors. Many exhibit activity as 5-HT1A antagonists in pharmacological testing. The compounds of the invention can be used for the treatment of CNS disorders, such as anxiety in mammals, particularly humans. They may also be used as antidepressants, hypotensives and as agents for regulating the sleep/wake cycle, feeding behaviour and/or sexual function.
- The compounds of the invention were tested for 5-HT1A receptor binding activity in rat hippocampal membrane homogenate by the method of B S Alexander and M D Wood, J Pharm Pharmacol, 1988, 40, 888-891.
- The compounds of Examples 3, 4, and 17, which are representative compounds of the invention, had IC₅₀'s of respectively 2.2, 5.8 and 3 nM in this test procedure.
- The compounds are tested for 5-HT1A receptor antagonism activity in a test involving the antagonism of 5-carboxamidotryptamine in the guinea-pig ileum in vitro (based upon the procedure of Fozard et al, Br J Pharmac, 1985, 86, 601P). The results for representative compounds of the invention are given below. The compound of Example 3 had a pA₂ of 8.7 and that of Example 4 had a pA₂ of 7.8 and that of Example 17 had a PA₂ of 9.8.
- The invention also provides a pharmaceutical composition comprising a compound or a pharmaceutically acceptable acid addition salt thereof in association with a pharmaceutically acceptable carrier. Any suitable carrier known in the art can be used to prepare the pharmaceutical composition. In such a composition, the carrier is generally a solid or liquid or a mixture of a solid or liquid.
- Solid form compositions include powders, granules, tablets, capsules (eg hard and soft gelatine capsules), suppositories and pessaries. A solid carrier can be, for example, one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, fillers, glidants, compression aides, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99%, eg from 0.03 to 99%, preferably 1 to 80% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
- The term "composition" is intended to include the formulation of an active ingredient with encapsulating material as carrier to give a capsule in which the active ingredient (with or without other carriers) is surrounded by the carrier, which is thus in association with it. Similarly cachets are included.
- Liquid form compositions include, for example, solutions, suspensions, emulsions, syrups, elixirs and pressurised compositions. The active ingredient, for example, can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilisers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, eg cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols, eg glycerol and glycols) and their derivatives, and oils (eg fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.
- Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. When the compound is orally active it can be administered orally either in liquid or solid composition form.
- Preferably the pharmaceutical composition is in unit dosage form, eg as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged composition, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquid. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. The quantity of the active ingredient in unit dose of composition may be varied or adjusted from 0.5 mg or less to 750 mg or more, according to the particular need and the activity of the active ingredient.
- The following Examples illustrate the invention. Examples 1,2,7,9,10,12-16,18,19,21-29,32 and 34-45 illustrate the preparation of intermediates and these intermediates, apart from the intermediate of Example 2, are not claimed in the present specification. The compound of Example 2 is provided by the present invention.
- A stirred solution of 2-chloro-N-(2-pyridinyl)acetamide (9.9g, 58 mmol) in dry DMF (40 ml) at 0°C was treated with 1-(2-methoxyphenyl)piperazine (11.1g 58 mmol) in dry DMF (40 ml), treated with potassium carbonate (9.2g, 67 mmol), after 30 min warmed to room temperature and after 18h treated with water (400 ml). The emulsion was extracted with ether (3 x 200 ml) and the extracts washed with water (500 ml), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. Purification by chromatography (silica; ethyl acetate) gave the product (17.3g) as an oil which crystallised on standing, m.p. 86-89°C.
- A solution of the product of Example 1 (13.87g, 42.5 mmol) in THF (150 ml) was heated under reflux under Ar, treated dropwise with borane-dimethyl sulphide (8 ml, 84.3 mmol), after 2½ h treated dropwise with methanol (50 ml) and treated with ¼N-HCl (200 ml). After 1 hr the reaction mixture was cooled to room temperature, washed with ethyl acetate (2 x 200 ml), basified with 2N-NaOH, and extracted with ethyl acetate (2 x 200 ml). The extracts were dried (Na₂SO₄) and evaporated in vacuo to give the product as an oil (11.8g). The product was purified by chromatography [silica, ethyl acetate-ethanol (20:1)] and converted to the salt-form with ethereal-hydrogen chloride. Crystallisation from acetonitrile gave the trihydrochloride salt of the product as white crystals, m.p. 212-214°C.
(Found: C, 50.8; H, 6.7; N, 13.2 C₁₈H₂₄N₄O.3HCl.¼H₂0 requires C, 50.7; H, 6.5; N, 13.1%). - A stirred suspension of potassium hydride, 35 wt.% suspension in mineral oil (2.99g, ca. 26.1 mmol) in DMF (25 ml) was treated dropwise under Ar with the free base of Example 2 (2.14g, 6.9 mmol) in DMF (15 ml). The reaction mixture was treated dropwise after 20 min with cyclohexanecarbonyl chloride (1.4 ml, 10.5 mmol), and after 1 hr treated carefully with water (200 ml), acidified with 2N-HCl (ca. 70 ml), washed with hexane (2 x 200 ml), basified with 2N-NaOH, and extracted with ethyl acetate ( 2 x 200 ml). The extracts were washed with brine (100 ml), dried (Na₂SO₄), and evaporated in vacuo to give a red oil which was purified by chromatography (silica; ethyl acetate). A solution of the oil in methanol (40 ml) was acidified with ethereal hydrogen chloride and evaporated in vacuo to give the trihydrochloride salt of the product (1.04g), m.p. 165-172°C (dec.)
(Found: C, 54.2; H, 7.3; N, 10.0% C₂₅H₃₄N₄O₂.3HCl.H₂0 requires C, 54.6; H, 7.15; N 10.2%). - A stirred suspension of potassium hydride, 35 wt. % suspension in mineral oil (2.91g, ca. 21.8 mmol) in dry DMF (20 ml) was treated dropwise with the free base of Example 2 (2.92 g, 9.4 mmol) in dry DMF (15 ml) under Ar. After 1 h the reaction mixture was treated with cyclohexyl isocyanate (1.3 ml, 10.2 mmol) and after a further 18 h treated with water (200 ml), acidified with 2N-HCl (ca. 50 ml), washed with hexane (2 x 200 ml), basified with 2N-NaOH, and extracted with ethyl acetate (2 x 200 ml). The extracts were washed with brine (200 ml), dried (Na₂SO₄), and evaporated in vacuo to give a brown oil which was purified by chromatography (silica; ethyl acetate, then alumina; ether). The colourless oil was dissolved in ethanol (10 ml) and the solution acidified with ethereal hydrogen chloride and evaporated in vacuo to give the trihydrochloride salt of the product as a hydrated glass containing a quarter mole of ethyl acetate (0.456g)
(Found: C, 53.2; H, 7.5; N, 11.8. C₂₅H₃₅N₅O₂.3HCl.H₂O. ¼C₄H₈O₂ requires C, 53.2; H, 7.2; N, 11.9%). - Benzoyl chloride (1.69g, 12 mmol) was added cautiously to a stirred solution of Example 2 free base (1.94g, 6 mmol) and di-isopropylethylamine (2.2 ml, 14 mmol) in dichloromethane (20 ml). The mixture was stirred under Ar for 24 h, evaporated in vacuo, and the brown oil dissolved in water (50 ml). The solution was acidified with 2N-HCl, washed with dichloromethane (3 x 50 ml), basified with 2N-NaOH, and extracted with dichloromethane (3 x 75 ml). The extracts were dried (MgSO₄), evaporated in vacuo, and the residue purified by chromatography [alumina; toluene-ethyl acetate (7:3)]. The oil was dissolved in ethyl acetate (10 ml) and the dihydrochloride salt of the product precipitated with ethereal hydrogen chloride as colourless crystals (1.3g), m.p. 105-112°C
(Found: C, 61.6; H, 6.1; N, 11.3, C₂₅H₂₈N₄O₂.2HCl requires C, 61.4; H, 6.2; N, 11.5%). - This compound was synthesised by an analogous method to that used for Example 5, substituting trimethylacetyl chloride (1.57g, 13 mmol) for benzoyl chloride, to give the trihydrochloride salt of the product (1.2g) as a white solid, m.p. 138-140°C
(Found: C, 53.5; H, 7.3; N, 10.8. C₂₃H₃₂N₄O₂.3HCl.½H₂O requires C, 53.7; H, 7.1; N, 10.9%). - Cyclohexanecarbonyl chloride (4.38g, 30 mmol) was added dropwise to a solution of 2-aminothiazole (3.00g, 30 mmol) and di-isopropylethylamine (3.87g, 30 mmol) in dichloromethane (50 ml) at 0°C. The mixture was warmed to room temperature, stirred for 18 h, washed with 1 N-HCl (2 x 50 ml) and 1 N-NaOH (2 x 50 ml), dried (MgSO₄), and evaporated in vacuo to give the product (4.59g) as white crystals.
- A solution of the product of Example 7 (2.10g, 10 mmol) in DMF was added dropwise to a stirred suspension of potassium hydride, 35 wt. % suspension in mineral oil (1.6g, ca 14 mmol) in DMF (20 ml) under Ar. After 1 h, 1-(2-chloroethyl)-4-(2-methoxyphenyl)piperazine (2.53g, 10 mmol) was added portionwise and the mixture stirred at 80°C for 5 h. Saturated aq. Na₂CO₃ (20 ml) was added cautiously and the mixture concentrated in vacuo. The residue was taken up into ether (100 ml) and extracted with 1N-HCl (3 x 50 ml). The aqueous phases were basified with 1N-NaOH and extracted with ether (3 x 50 ml). The ethereal extracts were dried (MgSO₄), evaporated in vacuo, and the residue purified by chromatography (silica; ethyl acetate). The oil was dissolved in ethyl acetate (10 ml) and the dihydrochloride salt of the product precipitated with ethereal hydrogen chloride as a white solid (1.1g), m.p. 205°C (a phase change was observed at 80°C and the sample decomposed at 205°C).
(Found: C, 53.4: H, 6.8: N, 10.7. C₂₃H₃₂N₄O₂S 2HCl.¾ H₂O requires C, 53.6; H, 7.0; N, 10.9%). - A stirred solution of 2-chloro-N-(2-pyridinyl)acetamide (0.94g, 5.5 mmol) in dry DMF (10 ml) was treated with 1-(4-fluoro-2-methoxyphenyl)piperazine (1.16g, 5.5 mmol) and di-isopropylethylamine (1.1 ml, 6.3 mmol), and after 19h treated with water (50 ml). The emulsion was extracted with ether (2 x 50 ml) and the extracts washed with water (100 ml), dried
(MgSO₄) and evaporated in vacuo to give a yellow oil. Purification by chromatography (silica; ether) gave the product (1.61g) as colourless crystals, m.p. 110-120°C (sample softens at 32°C). - A solution of the product of Example 9 (1.51g, 4.4 mmol) in THF (20 ml) was heated under reflux under Ar and treated dropwise with borane-methyl sulphide complex, 2M solution in THF (4.4 ml, 8.8 mmol). After 4 h the reaction mixture was treated dropwise with methanol (10 ml) and treated with 2N-HCl (10 ml). After 1 hr the reaction mixture was cooled to room temperature, treated with water (100 ml), basified with 2N-NaOH, and extracted with ethyl acetate (2 x 100 ml). The extracts were washed with brine (50 ml), dried (MgSO₄), and evaporated in vacuo to give the product as a yellow oil (1.29 g) which was used in the next Example without further purification.
- A stirred solution of the product of Example 10 (1.26g, 3.8 mmol) in dichloromethane (20 ml) under Ar was treated with di-isopropylethylamine (1.4 ml, 8.4 mmol) and cyclohexanecarbonyl chloride (1 ml, 7.5 mmol), washed after 24 hr with water (20 ml), saturated aq. NaHCO₃, (20 ml), and water (20 ml), dried (MgSO₄) and evaporated in vacuo to give a yellow oil which was purified by chromatography (silica; ethyl acetate). A solution of the oil in methanol (5 ml) was acidified with ethereal hydrogen chloride and evaporated in vacuo to give the trihydrochloride salt of the product (10.5g, 30%), m.p. 160-172°C.
(Found: C, 54.7; H, 6.4; N, 10.1% C₂₅H₃₃FN₄O₂.3HCl requires C, 54.6; H, 6.6; N 10.2%). - 1,2-Dibromoethane (12.0 g, 0.064 mol), potassium carbonate (17.6 g, 0.127 mol) and tetra-n-butyl ammonium bromide (1.37 g, 0.0043 mol) were added to a stirred solution of 3-nitrocatechol (6.59 g, 0.043 mol) in toluene (210 ml). The solution was heated at reflux with azeotropic removal of water for 23 h, cooled to room temperature, washed with 2N sodium hydroxide solution (150 ml), dried (Na₂SO₄), and evaporated in vacuo to give an orange oil. Purification by column chromatography (silica; ether) gave the product (2.55 g), m.p. 55-59°C.
- Ammonium formate (3.40 g, 0.054 mol) and 10% palladium on charcoal (1.44 g) were added to a stirred solution of the product of example 12 (2.45 g, 0.0135 mol) in methanol (15 ml). After the considerable effervescence had ceased, the mixture was filtered, evaporated in vacuo and triturated with acetonitrile. The residue was purified by chromatography (silica; ether) to give the product (1.51 g).
- The solution of the product of example 13 (1.50 g, 0.010 mol) and bis(2-chloroethyl)amine hydrochloride (1.77 g 0.01 mol) in chlorobenzene (20 ml) was heated under reflux for 24 h, cooled to room temperature and evaporated in vacuo. The white solid was dissolved in aqueous sodium hydroxide (100 ml) and extracted into ethyl acetate (3 x 50 ml). The extracts were dried (MgSO₄) and evaporated in vacuo to give the product (2.00 g).
- A stirred solution of 2-chloro-N-(2-pyridinyl)acetamide (9.9 g, 58 mmol) in dry DMF (40 ml) at 0°C was treated with the product of example 14 (58 mmol) in dry DMF (40 ml), treated with potassium carbonate (9.2 g, 67 mmol), after 30 min warmed to room temperature and after 18 h treated with water (400 ml). The emulsion was extracted with ether (3 x 200 ml) and the extracts washed with water (500 ml), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. Purification by chromatography (silica; ethyl acetate) gave the product as an oil.
- A solution of the product of Example 15 (42.5 mmol) in THF (150 ml) was heated under reflux under Ar, treated dropwise with borane-dimethyl sulphide (8 ml, 84.3 mmol), after 2½ h treated dropwise with methanol (50 ml) and treated with ¼N-HCl (200 ml). After 1 h the reaction mixture was cooled to room temperature, washed with ethyl acetate (2 x 200 ml), basified with 2N-NaOH, and extracted with ethyl acetate (2 x 200 ml). The extracts were dried (Na₂SO₄) and evaporated in vacuo. Purification by chromatography, [silica; ethyl acetate - ethanol (20:1)] gave the product as an oil.
- A stirred suspension of potassium hydride, 35 wt.% suspension in mineral oil (2.99 g, ca. 26.1 mmol) in DMF (25 ml) was treated dropwise under Ar with the product of Example 16 (6.9 mmol) in DMF (15 ml). The reaction mixture was treated dropwise after 20 min with cyclohexanecarbonyl chloride (1.4 ml, 10.5 mmol), and after 1 h treated carefully with water (200 ml), acidified with 2N-HCl (ca. 70 ml), washed with hexane (2 x 200 ml), basified with 2N-NaOH, and extracted with ethyl acetate (2 x 200 ml). The extracts were washed with brine (100 ml), dried (Na₂SO₄), and evaporated in vacuo to give a red oil which was purified by chromatography (silica; ethyl acetate). A solution of the oil in methanol (40 ml) was acidified with ethereal hydrogen chloride and evaporated in vacuo to give the hydrochloride salt of the product (1.04 g), m.p. 125-131°C.
(Found: C, 62.6; H, 7.3; N, 11.0 C₂₆H₃₄N₄O₂.HCl.¾H₂0 requires C, 62.4; H, 7.35; N 11.2%) - A solution of 3-piperazino-1,2-benzisothiazole (2.06 g, 6.4 mmol) in DMF (10 ml) was treated with N,N-diisopropylethylamine (2 ml, 12.3 mmol), treated with N-(2-pyridinyl)chloroacetamide (1.84 g, 9.6 mmol) in DMF (10 ml), stirred for 63 h, treated with water (150 ml), and extracted with ethyl acetate (3 x 50 ml). The extracts were evaporated in vacuo and the residue purified by chromatography (silica; ethyl acetate) to give the product as a foam (2.63 g).
- Borane-methyl sulphide complex (10M; 4.0ml, 40 mmol) was added dropwise to a stirred solution of the product of Example 18 (2.63 g, 7.44 mmol) in THF (26ml) under Ar. After 18 h, the solution was cooled to 0°C, treated with methanol (10 ml), water (10 ml) and concentrated aq. HCl (10 ml), heated to reflux, cooled to room temperature and evaporated in vacuo. The yellow solid residue was treated with water (50 ml) and 12.5 N NaOH (16 ml). The mixture was extracted with CH₂Cl₂ (2 x 50 ml) and the extracts dried (Na₂SO₄), evaporated in vacuo and the gum chromatographed (Al₂O₃; ethyl acetate) to give the product as a clear pink oil (0.986 g).
- A solution of cyclohexanecarbonyl chloride (0.40 ml, 3.0 mmol) in CH₂ Cl₂ (25 ml) was added dropwise to a stirred solution of the product of Example 19 (0.99 g, 2.90 mmol) and C₅H₅N (0.32 ml, 4.0 mmol) in CH₂ Cl₂ (10 ml) at 0°C under Ar. The orange solution was stirred at room temperature for 18 h, washed with water (25 ml) and saturated aq. NaHCO (10 ml), dried (Na₂SO₄) and evaporated in vacuo to give an orange oil which was chromatographed (SiO₂; ethyl acetate) to give the product (0.84 g). The hydrochloride salt was prepared in standard fashion and crystallised by trituration with acetonitrile to give colourless crystals (0.84 g) m.p. 174°-176°C.
Found: C, 56.92; H, 6.64; N 13.24% C₂₅H₃₁N₅OS. 2HCl.0.25H₂0 requires C, 56.97; H, 6.41; N, 13.29%. - A solution of 1-chloroisoquinoline (1.64 g 10 mmol) in dry DMF (5 ml) was added to a stirred solution of 1-benzylpiperazine (1.85 g, 10.5 mmol) and N,N-diisopropylethylamine (2 ml, 1.5 g, 11.5 mmol) in dry DMF (5 ml) under Ar at room temperature. The solution was stirred at room temperature for 17 h. The yellow solution was heated at 110°C for 7 h, treated with water (100 ml) and extracted with ether ( 2 x 50 ml). The extracts were dried (Na₂SO₄) and concentrated in vacuo. The residue was chromatographed (Si0₂; ethyl acetate) to give the product (1.233 g).
- Ammonium formate (1.01 g, 16.0 mmol) and 10% Pd/C 42.5 mg, 0.4 mmol, 10 mol%) were added successively to a stirred solution of the product of Example 21 (1.23 g, 4.06 mmol) in methanol (4 ml). The mixture was stirred at room temperature for 6 h and was heated at 75°C for 16 h. Methanol (40 ml) was added and the mixture filtered through Kieselguhr, and concentrated in vacuo to give the product as a pale yellow oil.
- Bis(2-chloro)ethylamine hydrochloride (8.70 g, 48.7 mmol) was added to a stirred solution of 5,6,7,8-tetrahydro-1-naphthylamine (4.78 g 3 .5 mmol) in chlorobenzene (90 ml). The mixture was heated at 140°C for 38 h and cooled to room temperature. The precipitate was collected and washed with a minimum volume of chlorobenzene. Recrystallisation from ethanol gave the hydrochloride salt of the product as white crystals (2.4 g), m.p. 324°C (decomp).
Found: C, 66.8; H, 8.5; N, 11.1. C₁₄H₂0N₂.HCl requires: C, 66.5; H, 8.4; N 11.1%. - (S)-1-(2-Aminopropyl))-4-(2-methoxyphenyl)piperazine (25 g, 100 mmol) was stirred with 2-fluoropyridine (2.6 ml, 30 mmol) in a bomb at 130°C for 10 days. The resulting dark residue was dissolved in 150 ml water and basified with sodium hydroxide solution. The mixture was shaken with three portions of chloroform and the chloroform solution washed with water and dried over magnesium sulphate. The residual black oil (20 g) was chromatographed (silica), eluting with ethyl acetate to yield the product (1.84 g) as an oil.
- (R)-(1-(2-(2-Pyridylamino)propyl))-4-(2-methoxyphenyl)piperazine was prepared from (R)-(1-(2-aminopropyl))-4-(2-methoxyphenyl)piperazine (30.8 g, 123 mmol) and 2-fluoropyridine (3.0 ml, 27.4 mmol) by the method described for Example 24 as an oil (5 g).
- A solution of acrylonitrile (1.06 g, 20 mmol) in ethanol (50 ml) was added to a stirred solution of 2-methoxyphenylpiperazine (3.84 g, 20 mmol) in ethanol (100 ml). After 18 h, the solvent was evaporated in vacuo to give the product (4.5 g) as a white solid.
- A solution of the product of Example 26 (4.4 g, 18 mmol) in concentrated ethanolic ammonia solution (150 ml) was hydrogenated over 5% rhodium on alumina powder (0.6 g) at 50 p.s.i. (about 3.4 x 10⁵Pa) for 50 h to give the product (3.9 g) as a brown oil.
- The product of Example 27 (3.9 g, 16 mmol) and 2-chloropyridine (1.82 g, 16 mmol) were heated at 160°C in a sealed vessel for 6 h. After cooling, the residue was taken up into CH₂Cl₂ (50 ml) washed with aqueous NaOH (3 x 50 ml), dried (MgSO₄) and evaporated in vacuo. The residue was purified by chromatography [alumina; ethyl acetate - toluene (1:4)] to give the product (0.7 g) as a brown oil.
- 1-(2-aminoethyl)-4-(2-methoxyphenyl)piperazine (9.4 g, 40 mmol) and 2-chloroquinoline (6.5 g, 40 mmol) were heated at 160°C for 3 h, then at 120°C for 18 h in a sealed vessel. The resultant brown tar was taken up into dilute hydrochloric acid (300 ml), washed with dichloromethane (3 x 100 ml) basified with sodium hydroxide, extracted into dichloromethane (3 x 100 ml), dried (MgSO₄) then evaporated in vacuo to give a brown oil. The oil was purified by chromatography [alumina; ethyl acetate - toluene (1:4)] to give the product (1.8 g) as a clear oil.
- A stirred solution of the product of Example 2 (1 g, 3.2 mmol) in toluene (50 ml) was treated with diisopropylethylamine (0.84 ml, 4.8 mmol), treated dropwise with phosgene, about 12½% w/w solution in toluene (7.5 ml, about 8.6 mmol) with water-bath cooling under an atmosphere of Ar, after 1 h treated with piperidine (1.5 ml, 15 mmol), after 18 h treated with water (100 ml) and extracted with ethyl acetate (2 x 100 ml). The extracts were washed with water (100 ml), dried (MgSO₄), and evaporated in vacuo. The oil was purified by chromatography [silica, ethyl acetate - ethanol (20:1)], dissolved in ethanol (10 ml) and acidified with ethereal hydrogen chloride. Evaporation in vacuo gave the product as a pink glass (0.43 g), m.p. softens above 70°C.
Found: C, 50.2; H, 7.4; N, 10.7. C₂₄H₃₃N₅0₂.3HCl. 2½H₂0.1½ EtOH requires C, 50.1; H, 7.8; N, 10.8% - A suspension of the product of Example 2 (3.12 g, 10 mmol) in DMSO (50 ml) was added to KH, 35 wt. % dispersion in mineral oil (1 g, 8.7 mmol) under Ar. After 1 h, cyclohexylisothiocyanate (1.41 g, 10 mmol) was added and the mixture was stirred at 80°C for 16 h, cooled to room temperature, and poured onto 2N-HCl (500 ml). The mixture was washed with ethyl acetate (3 x 200 ml), basified with NaOH, and extracted with ethyl acetate (3 x 100 ml). The extracts were dried (MgSO₄) and evaporated in vacuo to give an oil which was purified by chromatography [alumina; ethyl acetate-hexane (1:4)]and radial chromatography [silica; chloroform-ethanol (100:1)] to give the product (0.1 g) as an oil.
(Found: C, 66.3; H, 7.8: N, 15.4. C₂₅H₃₅N₅0S requires C, 66.2; H, 7.8; N, 15.4%). - The product of Example 2 (5.25 g, 16.8 mmol) in DMF (40 ml) was treated with potassium tert-butoxide (4.53 g, 40 mmol) under Ar, treated with propanethiol (3.14 g, 41.3 mmol), stirred at 100°C for 18 h, cooled to room temperature, and poured onto water (200 ml). The mixture was extracted with ethyl acetate (3 x 80 ml) and the organic phases combined, washed with water (40 ml), dried (MgSO₄) and evaporated in vacuo. Purification by chromatography [alumina; hexane-ethyl acetate (1:1)] gave the product as an oil (2.79 g). The trihydrochloride salt was a colourless solid, m.p. 260-265°C.
- A solution of the product of Example 32 (0.87 g, 2.9 mmol) in dichloromethane (10 ml) was treated with pyridine (0.46 g, 5.8 mmol) and cyclohexanecarbonyl chloride (0.85 g, 5.8 mmol). The mixture was stirred for 18 h, evaporated in vacuo, treated with 10% NaOH (10 ml) and ethanol (10 ml), stirred for 2 h, acidified with dil. HCl (which cleaved the phenol ester), basified with saturated aq. NaHCO₃, and extracted with dichloromethane (3 x 30 ml). The extracts were washed with water (30 ml), dried (MgSO₄), and evaporated in vacuo. The oil was purified by chromatography (silica; ethyl acetate) to give the product (1.09 g) as an oil. The hydrochloride salt was formed in the usual manner as a colourless powder, m.p. 220-223°C
(Found: C, 61.5; H, 7.6; N, 11.4. C₂₄H₃₂N₄O₂. 1½HCl ¼H₂O requires C, 61.6; H, 7.3: N, 12.0% - The following compounds were prepared by a procedure which was analogous to that described in Example 18.
- (a) Example 34
N-(2-Pyridinyl)-2-(1-(4-(1-naphthyl)piperazinyl))-acetamide was prepared from 1-(1-naphthyl)piperazine hydrochloride (2.49 g, 10 mmol) and N-(2-pyridinyl)chloroacetamide (1.69 g, 9.9 mmol) as colourless crystals (3.01 g), m.p. 171-173°C
(Found: C, 72.5; H, 6.35; N, 16.1. C₂₁H₂₂N₄O requires C, 72.8; H, 6.4; N, 16.2%) - (b) Example 35
2-(1-(4-(2-Methylphenyl)piperazinyl))-N-(2-pyridinyl)acetamide was prepared from ortho-tolylpiperazine hydrochloride (3.19 g, 15 mmol) and N-(2-pyridinyl)-2-chloroacetamide (2.56 g, 15.0 mmol) as a yellow gum (4.63 g). - (c) Example 36
2-(1-(4-(1-Isoquinolinyl)piperazinyl))-N-(2-pyridyl)acetamide was prepared from the product of Example 22 (707 mg, 3.3 mmol) and N-(2-pyridyl)chloroacetamide (568 mg, 3.33 mmol) as a yellow oil (1.16 g) - (d) Example 37
2-(1-(4-(1-(7-Methoxy)naphthyl)piperazinyl))-N-(2-pyridyl)acetamide was prepared from 1-[1-(7-methoxy)]naphthyl piperazine (3.33 g, 13.8 mmol) and N-(2-pyridyl)chloroacetamide (1.88 g, 11.0 mmol), as a solid (3.125 g) m.p. 142°-144°C
(Found: C, 68.6; H, 6.6; N 14.3 C₂₂H₂₄N₄O₂0.5H₂O requires: C, 68.55; H, 6.5; N, 14.5%) - (e) Example 38
2-(1-(4-(1-(2-Methoxy)naphthyl)piperazinyl))-N-(2-pyridyl)acetamide was prepared from 1-[1-(2-methoxy)naphthyl]piperazine hydrochloride three quarters hydrate (1.75 g, 5.99 mmol) and N-(2-pyridyl)chloroacetamide (1.08 g, 6.33 mmol) as a solid (1.71 g), m.p. 184-185°C (from ether)
(Found: C, 69.9; H, 6.5; N, 14.8 C₂₂H₂₄N₄O₂ requires C, 70.2; H, 6.4; N, 14.9%) - (f) Example 39
2-(1-(4-(1-(5,6,7,8-Tetrahydro)naphthyl)piperazinyl))-N-(2-pyridyl)acetamide was prepared from the product of Example 23 (2.88 g, 9.96 mmol) and N-(2-pyridyl)chloroacetamide as a colourless gum (2.50 g) - The following compounds were prepared by a procedure which was analogous to that described for Example 19.
- (a) Example 40
2-(1-(4-(1-Napthyl))piperazinyl)-N-(2-pyridinyl)ethylamine was prepared from the product of Example 34 (2.965 g, 8.6 mmol) and borane-methyl sulphide complex (10 M; 4.0 ml, 40 mmol) as an oil (2.33 g) - (b) Example 41
2-(1-(4-(2-Methylphenyl))piperazinyl)-N-(2-pyridinyl)ethylamine was prepared from the product of Example 35 (4.63 g, 14.9 mmol) as a colourless oil (3.235 g). - (c) Example 42
2-[1-[4-(1-Isoquinolinyl)piperazinyl]]-N-(2-pyridyl)ethylamine was prepared from the product of Example 36 (975 mg, 2.8 mmol) and borane-methyl sulphide complex (10 M; 1.4 ml, 14 mmol) as an oil (0.695 g) - (d) Example 43
2-[1-[4-[1-(7-Methoxy)naphthyl]]piperazinyl]-N-(2-pyridyl)ethylamine was prepared from the product of Example 37 (3.0 g, 8.0 mmol) and borane-methyl sulphide complex (10 M; 4.0 ml, 40 mmol) as an oil (2.57 g). - (e) Example 44
2-[1-[4-[1-(2-Methoxy)naphthyl]]piperazinyl]-N-(2-pyridyl)ethylamine was prepared from the product of Example 38 (1.665 g, 4.4 mmol) and borane-methyl sulphide complex (2.4 ml, 24 mmol) as a yellow oil (1.229 g). - (f) Example 45
2-[1-[4-[1-(5,6,7,8-Tetrahydro)naphthyl]]piperazinyl]-N-(2-pyridyl)ethylamine was prepared from the product of Example 39 (2.50 g, 7.1 mmol) and borane-methyl sulphide complex (10 M; 3.8 ml, 38 mmol) as a colourless gum (1.96 g). - The following compounds were prepared by a procedure analogous to that described for Example 20
- (a) Example 46
N-(2-(1-(4-(1-Naphthyl))piperazinyl)ethyl)-N-(2-pyridyl)cyclohexanecarboxamide was prepared from the product of Example 40 (2.33 g, 7.0 mmol) and cyclohexanecarbonyl chloride (0.94 ml, 7.0 mmol). The dihydrochloride salt was produced as a colourless solid (2.56 g), m.p. 188-190°C
(Found: C, 65.3; H, 7.1; N, 10.8. C₂₈H₃₄N₄O.2HCl requires C, 65.2; H, 7.0; N, 10.9%). - (b) Example 47
N-(2-(1-(4-(2-Methylphenyl))piperazinyl)ethyl)-N-(2- pyridinyl)cyclohexanecarboxamide was prepared from the product of Example 41 (3.235 g, 10.9 mmol) as a dihydrochloride salt (3.66 g), m.p. 191-199°C
(Found: C, 60.3; H, 7.65; N, 11.3 C₂₅H₃₄N₄O 2HCl.H₂O requires C, 60.4; H, 7.7; N, 11.3%). - (c) Example 48
N-(2-(1-(4-(2-Fluorophenyl))piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide maleate hydrate was prepared as a white solid, m.p. 121-127°C
(Found: C, 61.75; H, 6.7; N, 10.2 C₂₄H₃₁FN₄0 requires C, 61.75; H, 6.85; N, 10.3%) - (d) Example 49
N-[2-[1-[4-(1-Isoquinolinyl)]piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide was prepared from the product of Example 42 (695 mg, 2.1 mmol) and cyclohexanecarbonyl chloride (0.3 ml, 2.2 mmol). The trihydrochloride salt was a colourless solid (0.392 g) m.p. 145°C.
(Found: C, 55.35; H, 7.01; N, 11.99 C₂₇H₃₃N₅O. 3HCl.2H₂O requires C, 55.06; H, 6.85; N, 11.89%) - (e) Example 50
N-[2-[1-[4-[1-(7-Methoxy)naphthyl]]piperazinyl]ethyl]-N -(2-pyridyl)cyclohexanecarboxamide was prepared from the product of Example 43 (2.57 g, 7.1 mmol) and cyclohexane carbonyl chloride (1.75 g, 12 mmol). The hydrochloride salt was a low melting solid (2.36 g) m.p. 90°C (slowly decomposes above this temperature).
(Found: C, 66.17; H, 7.35; N, 10.38; C₂₉H₃₆N₄O₂ HCl.H₂O requires C, 66.08; H, 7.46; N, 10.63%). - (f) Example 51
N-(2-(1-(4-(2-Methoxyphenyl)piperazinyl))ethyl)-N-(2-pyridyl)adamantane-1-carboxamide was prepared from the product of Example 2 and adamantane-1-carbonyl chloride. The dihydrochloride salt was a white solid, m.p. 132-136°C
(Found: C, 58.6; H, 7.5; N, 9.2. C₂₉H₃₈N₄O₂. 2HCl.2½H₂O requires C, 58.8; H, 7.65; N, 9.45%). - (g) Example 52
N-[2-[1-[4-[1-(2-Methoxy)naphthyl]]piperazinyl]ethyl]-N-[2-pyridyl)cyclohexanecarboxamide was prepared from the product of Example 44 (1.23 g, 3.4 mmol) and cyclohexanecarbonyl chloride (0.7 ml, 0.8 g, 5.2 mmol). The dihydrochloride salt was obtained as colourless crystals (0.83 g), m.p. 151-156°C
(Found: C, 63.6; H, 7.1; N, 10.6. C₂₉H₃₆N₄O₂. 2HCl requires C, 63.85; H, 7.0; N, 10.3%). - (h) Example 53
N-[2-[1-[4-[1-(5,6,7,8-Tetrahydro)naphthyl]]-piperazinyl]ethyl]-N-(2-pyridyl)cyclohexanecarboxamide was prepared from the product of Example 45 (1.96 g, 5.8 mmol) and cyclohexanecarbonyl chloride (1 ml, 1.1 g, 7.5 mmol). The dihydrochloride salt was obtained (2.21 g), m.p. 178-180°C
(Found: C, 64.6; H, 7.8; N, 10.9. C₂₈H₃₈N₄O.2HCl requires C, 64.7; H, 7.8; N, 10.8%) - (i) Example 54
(S)-N-(1-Methyl-2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexane carboxamide was prepared from the product of Example 24 (1.84 g, 5.6 mmol) and cyclohexanecarbonyl chloride (0.8 ml, 5.6 mmol). The trihydrochloride salt was prepared as crystals (1.29 g) m.p. 178-180°C, [α]
(Found: C, 57.7; H, 7.5; N , 10.32. C₂₆H₃₆N₄O₂. 3HCl requires C, 57.2; H, 7.2; N, 10.26%) - (j) Example 55
(R)-N-(1-Methyl-2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexane carboxamide was prepared from the product of Example 25 (1.87 g, 5.7 mmol) and cyclohexanecarbonyl chloride (0.8 ml, 5.6 mmol). The dihydrochloride salt was prepared as crystals (2.1 g), m.p. 175-180°C, [α]
(Found: C, 59.8; H, 7.8; N, 10.45. C₂₆H₃₆N₄O₂. 2HCl.¾H₂O requires C, 59.7; H, 7.6; N, 10.7%). - (k) Example 56
N-[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl]-N-(2-pyridinyl)cyclohexanecarboxamide was prepared from the product of Example 28 (0.7 g, 2.1 mmol) and cyclohexanecarbonyl chloride (0.63 g, 4.3 mmol). The trihydrochloride salt was a white solid (0.9 g), m.p. 137-141°C
(Found: C, 55.6; H, 7.3; N, 9.8. C₂₆H₃₆N₄O₂. 3HCl.H₂O requires C, 55.4; H, 7.3; N, 9.9%). - (l) Example 57
N-(2-(4-(2-Methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-quinolinyl)cyclohexane carboxamide was prepared from the product of Example 29 (1.8 g, 5 mmol) and cyclohexanecarbonyl chloride (1.42 ml, 10 mmol). The monohydrochloride salt was a white solid (2.31 g), m.p. 189-192°C
(Found: C, 66.7; H, 7.3; N, 10.5; C₂₉H₃₆N₄O₂. HCl. ¾H₂O requires C, 66.6; H, 7.4; N, 10.7%). - (m) Example 58
(Rac)-N-(2-(4-(2-Methoxyphenyl)-1-piperazinyl)propyl)-N-(2-pyridyl)cyclohexanecarboxamide was prepared from (rac)-4-(2-methoxyphenyl)-1-(2-(1-(2-pyridylamino)propyl))piperazine (2.28 g, 7 mmol) and cyclohexanecarbonyl chloride (1.03 ml, 7.7 mmol). The dihydrochloride salt (0.68 g) was obtained, m.p. 195-196°C (from ethanol-ether)
(Found: C, 60.7; H, 7.2; N, 10.9. C₂₆H₃₆N₄O₂. 2HCl. ¼H₂O requires C, 60.75; H, 7.55; N, 10.9%). - (n) Example 59
(S)-N-(2-(4-(2-Methoxyphenyl)-1-piperazinyl)propyl)-N-(2-pyridyl)cyclohexanecarboxamide was prepared from (S)-4-(2-methoxyphenyl)-1-(2-(1-(2-pyridylamino)propyl))piperazine [itself prepared from (R)-2-chloropropionyl chloride] by a method analogous to that used for Example 58. The trihydrochloride salt was a white solid, m.p. 129-130°C, [α]
(Found: C, 54.7; H, 7.2; N, 9.5. C₂₆H₃₆N₄O₂. 3HCl. 1½H₂O requires C, 54.5; H, 7.4; N, 9.8%). - (o) Example 60
(R)-N-(2-(4-(2-Methoxyphenyl)-1-piperazinyl)propyl-N-(2-pyridyl)cyclohexanecarboxamide was prepared in a fashion similar to that used for Example 59. - (p) Example 61
N-(2-(4-Phenyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide was prepared from 2-(4-phenyl-1-piperazinyl)-N-(2-pyridyl)ethylamine and cyclohexanecarbonyl chloride. The trihydrochloride salt was a white solid, m.p. 198-200°C
(Found: C, 57.2; H, 7.1; N, 11.1 C₂₄H₃₂N₄O. 3HCl requires C, 57.4; H, 7.0; N, 11.2%). - (q) Example 62
N-(2-(4-(2-Isopropylphenyl)-1-piperazinyl)ethyl)-N-(2-pyridyl)cyclohexanecarboxamide was prepared from 2-(4-(2-isopropylphenyl)-1-piperazinyl)-N-(2-pyridyl)ethylamine and cyclohexanecarbonyl chloride. The hydrochloride salt was a colourless powder, m.p. 168-170°C
(Found: C, 67.15; H, 8.2; N, 11.5 C₂₇H₃₈N₄O.HCl.¾H₂O requires C, 66.9; H, 8.4; N, 11.6%). - (r) Example 63
N-(2-(4-(2-Methoxyphenyl)-1-piperazinyl)ethyl)-N-(4-pyridinyl)cyclohexane carboxamide was prepared from 2-(4-(2-methoxyphenyl-1-piperazinyl))-N-(4-pyridyl)ethylamine (0.39 g, 1.2 mmol) and cyclohexanecarbonyl chloride (0.37 ml, 2.5 mmol). The trihydrochloride salt (0.15 g) was a colourless solid, m.p. 151-153°C.
(Found: C, 55.7; H, 7.3; N, 10.2 C₂₅H₃₄N₄O₂.3HCl.½H₂O requires C, 55.5; H, 7.1; N, 10.4). - (s) Example 64
N-(2-(4-(2-Methoxyphenyl)-1-piperazinyl)ethyl)-N-(3-pyridyl)cyclohexanecarboxamide was prepared from 2-(4-(2-methoxyphenyl)-1-piperazinyl)-N-(3-pyridyl)ethylamine and cyclohexanecarbonyl chloride. The dihydrochloride salt was a hygroscopic white solid, m.p. 138-140°C
(Found: C, 56.8; H, 7.8; N, 10.5 C₂₅H₃₄N₄O₂.2HCl. 2H₂O requires C, 56.7; H, 7.2; N, 10.6%). - (t) Example 65
N-(2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl)-N-(2-pyridinyl)cyclohex-1-enecarboxamide was prepared from the product of Example 2, (1.49 g, 5 mmol) and cyclohex-1-enecarbonyl chloride (1.08 g, 7.5 mmol) as a clear oil
(Found: C, 71.3: H, 7.9; N, 13.0. C₂₅H₃₂N₄O₂ requires C, 71.4; H, 7.7; N, 13.3%) - Phosphorous pentasulphide (2.0 g, 4.5 mmol) and sodium carbonate (0.47 g, 4.5 mmol) were added to THF (30 ml) and the resultant mixture was stirred vigorously with gentle warming until complete dissolution (30 min). The product of Example 3 (1.5 g, 3.55 mmol) in THF (10 ml) was added and the resultant mixture was stirred at room temperature for 16 h, boiled at reflux for 3 h and cooled to room temperature. Lawesson's reagent (1.5 g, 3.71 mmol) and dioxane (30 ml) were added and the mixture was boiled at reflux for 4 h. The cooled reaction mixture was washed into a solution of sodium hydroxide (10%, 100 ml) and dichloromethane (200 ml). The organic layer was separated and the aqueous layer extracted with dichloromethane (3 x 100 ml). The combined extracts were washed with brine (1 x 200 ml), dried (MgSO₄), filtered and concentrated in vacuo. The resultant oil (1.0 g) was chromatographed on silica gel using dichloromethane and then 2% methanol in dichloromethane as eluents to afford an oil (280 mg). This oil was rechromatographed on alumina twice using dichloromethane as eluent to give an oil (50 mg). This was dissolved in ethanol and the dihydrochloride salt of the product was crystallised by the addition of ethereal HCl (50 mg), m.p. 108-110°C
(Found: C, 58.5; H, 7.4; N, 10.85. C₂₅H₃₄N₄OS 2HCl requires C, 58.7; H, 7.1; N, 10.95%).
Claims (12)
- A process for preparing a compound of the general formula
A is an alkylene chain of 2 to 4 carbon atoms optionally substituted by one or more lower alkyl groups,
Z is oxygen or sulphur,
R is hydrogen or lower alkyl,
R¹ is a mono or bicyclic aryl or heteroaryl radical,
R² is a mono or bicyclic heteroaryl radical
and R³ is hydrogen, lower alkyl, cycloalkyl, cycloalkenyl, cycloalkyl(lower)alkyl, aryl, aryl(lower)alkyl, heteroaryl, heteroaryl(lower)alkyl, a group of formula -NR⁴R⁵ [where R⁴ is hydrogen, lower alkyl, aryl or aryl(lower)alkyl and R⁵ is hydrogen, lower alkyl, -CO(lower)alkyl, aryl, COaryl, aryl(lower)alkyl, cycloalkyl or cycloalkyl-(lower)alkyl or R⁴ and R⁵ together with the nitrogen atom to which they are both attached represent a saturated heterocyclic ring which may contain a further hetero atom] or a group of formula OR⁶ [where R⁶ is lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, aryl, aryl(lower)alkyl, heteroaryl or heteroaryl(lower)alkyl] which comprises(a) acylating an amine of formula (II)
R³CZOH (III)
(where Z and R³ are as defined above) or with an acylating derivative thereof, or(b) reacting an amine of formula (II)
R⁵NCZ
(where R⁵ and Z are as defined above),
or(c) acylating a compound of formula
or(d) alkylating an amide or thioamide of formula (IV)
or(e) alkylating a compound of formula
X-A . NR².CZ.R³ (V)
(where A, R, R¹, R², R³ and Z are as defined above and X is a leaving group)
or(f) heteroarylating a compound of formula(g) reacting a piperazine compound of formula
R¹F
where R¹ is a mono or bicyclic aryl or heteroaryl radical that is activated towards nucleophilic substitution
or(h) sulphurising a compound of formula (I) where Z is oxygen to give a compound of formula (I) where Z is sulphur
or(i) converting a base claimed of formula I into a pharmaceutically acceptable acid addition salt thereof
or(j) converting a pharmaceutically acceptable acid addition salt of a compound of formula I into a free base thereof. - A process as claimed in claim 1 in which A is -(CH₂)₂-, -(CH₂)₃-, -(CH₂)₄- or -CH(CH₃).CH₂-.
- A process as claimed in claim 1 or 2 in which R is hydrogen.
- A process as claimed in any one of claims 1 to 3 in which R¹ is o-methoxyphenyl, o-isopropylphenyl, 4-fluoro-2-methoxyphenyl, 2,3-dihydro[1,4]benzodioxan-5-yl, pyrimid-2-yl, 1-naphthyl, 3-(1,2-benzisothiazolyl), 1-(7-methoxynaphthyl) or 1-(5,6,7,8-tetrahydro)naphthyl.
- A process as claimed in any one of claims 1 to 4 in which R² is pyridyl-2-yl, quinolin-2-yl or thiazol-2-yl.
- A process as claimed in any one of claims 1 to 5 in which R³ is lower alkyl, cycloalkyl, cycloalkenyl, phenyl, piperidino or -NHcycloalkyl.
- A process as claimed in claim 1 in which the product is N-(2-(1-(4-(2-methoxyphenyl)piperazinyl))ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide or N-cyclohexyl-N'-(2-(1-(4-(2-methoxyphenyl)-piperazinyl))ethyl)-N-(2-pyridinyl)urea or N-(2-(1-(4-(2-methoxyphenyl)piperazinyl))ethyl)-N-(2-pyridinyl)benzamide or N-(2-(1-(4-(2-methoxyphenyl)piperazinyl))ethyl)-N-(2-pyridinyl)trimethylacetamide or N-(2-(1-(4-(2-methoxyphenyl)piperazinyl))ethyl)-N-(2-thiazolyl)cyclohexanecarboxamide or N-(2-(1-(4-(4-fluoro-2-methoxyphenyl)piperazinyl))-ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide or N-(2-(1-(4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazinyl))ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide or N-[2-[1-[4-[3-(1,2-benzisothiazolyl)]]piperazinyl]-ethyl]-N-(2-pyridyl)cyclohexanecarboxamide or N-(2-(1-(4-(2-methoxyphenyl)piperazinyl))ethyl)-N-(1-piperidinylcarbonyl)-2-aminopyridine or N-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-N-(pyridin-2-yl)-N'-cyclohexylthiourea or N-(2-(4-(2-hydroxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide or N-(2-(1-(4-(1-naphthyl))piperazinyl)ethyl)-N-(2- pyridyl)cyclohexanecarboxamide or N-(2-(1-(4-(2-methylphenyl))piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide or N-(2-(1-(4-(2-fluorophenyl))piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide or N-[2-[1-[4-(1-isoquinolinyl)]piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide or N-[2-[1-[4-[1-(7-methoxy)naphthyl]]piperazinyl]ethyl]-N-(2-pyridyl)cyclohexanecarboxamide or N-(2-(1-(4-(2-methoxyphenyl)piperazinyl))ethyl)-N-(2-pyridyl)adamantane-1-carboxamide or N-[2-[1-[4-[1-(2-methoxy)naphthyl]]piperazinyl]ethyl]-N-[2-pyridyl)cyclohexanecarboxamide or N-[2-[1-[4-[1-(5,6,7,8-tetrahydro)naphthyl]]piperazinyl]ethyl]-N-(2-pyridyl)cyclohexanecarboxamide or (S)-N-(1-methyl-2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexane carboxamide or (R)-N-(1-methyl-2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexane carboxamide or N-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-N-(2-pyridinyl)cyclohexanecarboxamide or N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-quinolinyl)cyclohexane carboxamide or (Rac)-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)propyl)-N-(2-pyridyl)cyclohexanecarboxamide or (S)-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)propyl)-N-(2-pyridyl)cyclohexanecarboxamide or (R)-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)propyl-N-(2-pyridyl)cyclohexanecarboxamide or N-(2-(4-phenyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide or N-(2-(4-(2-isopropylphenyl)-1-piperazinyl)ethyl)-N-(2-pyridyl)cyclohexanecarboxamide or N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(4-pyridinyl)cyclohexane carboxamide or N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(3- pyridyl)cyclohexanecarboxamide or N-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-N-(2-pyridinyl)cyclohex-1-enecarboxamide or N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexane thiocarboxamide
or a pharmaceutically acceptable salt thereof. - A process for preparing a pharmaceutical composition which comprises bringing a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable acid addition salt thereof into association with a pharmaceutically acceptable carrier.
- A process as claimed in claim 1 wherein the active ingredient is prepared by the process claimed in any one of claims 1 to 7.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9109475 | 1991-05-02 | ||
GB919109475A GB9109475D0 (en) | 1991-05-02 | 1991-05-02 | Piperazine derivatives |
GB919127189A GB9127189D0 (en) | 1991-12-21 | 1991-12-21 | Piperazine derivatives |
GB9127189 | 1991-12-21 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0512755A2 EP0512755A2 (en) | 1992-11-11 |
EP0512755A3 EP0512755A3 (en) | 1993-03-03 |
EP0512755B1 true EP0512755B1 (en) | 1994-12-14 |
Family
ID=26298819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92303918A Expired - Lifetime EP0512755B1 (en) | 1991-05-02 | 1992-04-30 | Piperazine derivatives |
Country Status (24)
Country | Link |
---|---|
US (1) | US6127357A (en) |
EP (1) | EP0512755B1 (en) |
JP (1) | JP3095521B2 (en) |
KR (1) | KR100203254B1 (en) |
CN (2) | CN1040106C (en) |
AT (1) | ATE115566T1 (en) |
AU (1) | AU645681B2 (en) |
BR (1) | BR9201624A (en) |
CA (1) | CA2067929C (en) |
CZ (1) | CZ286778B6 (en) |
DE (1) | DE69200893T2 (en) |
DK (1) | DK0512755T3 (en) |
ES (1) | ES2065133T3 (en) |
FI (1) | FI108720B (en) |
GB (1) | GB2255337B (en) |
HK (1) | HK1003001A1 (en) |
HU (2) | HU223527B1 (en) |
IE (1) | IE64634B1 (en) |
IL (1) | IL101722A (en) |
MX (1) | MX9201991A (en) |
MY (1) | MY107756A (en) |
RU (1) | RU2193561C2 (en) |
SK (1) | SK280133B6 (en) |
UA (1) | UA39917C2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972945A (en) * | 1997-06-13 | 1999-10-26 | Neurogen Corporation | 2-aminoalkylaminoquinolines; dopamine receptor subtype specific ligands |
US6313141B1 (en) | 1997-06-13 | 2001-11-06 | Neurogen Corporation | 2-aminoalkylaminoquinolines as dopamine D4 ligands |
US6828324B2 (en) | 1999-11-12 | 2004-12-07 | Wyeth | Branched adamantyl and noradamantyl aryl-and aralkylpiperazines with serotonin 5-HT1A activity |
US6831084B1 (en) | 1999-11-12 | 2004-12-14 | Wyeth | Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-HT1A activity |
US7049330B2 (en) | 1998-06-15 | 2006-05-23 | Wyeth | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU645681B2 (en) * | 1991-05-02 | 1994-01-20 | John Wyeth & Brother Limited | Piperazine derivatives |
GB9223153D0 (en) * | 1992-11-05 | 1992-12-16 | Wyeth John & Brother Ltd | Piperazine derivatives |
GB9300195D0 (en) * | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
GB9302622D0 (en) * | 1993-02-10 | 1993-03-24 | Wellcome Found | Heteroaromatic compounds |
GB9303968D0 (en) * | 1993-02-26 | 1993-04-14 | Wyeth John & Brother Ltd | 5-ht1a ligands |
GB9305672D0 (en) * | 1993-03-19 | 1993-05-05 | Wyeth John & Brother Ltd | Amide derivatives |
GB9306103D0 (en) * | 1993-03-24 | 1993-05-12 | Wyeth John & Brother Ltd | Piperazine derivatives |
FR2707294B1 (en) * | 1993-07-06 | 1995-09-29 | Pf Medicament | New derivatives of 3,5-dioxo- (2H, 4H) -1,2,4-triazine, their preparation and their application in human therapy. |
GB9314758D0 (en) * | 1993-07-16 | 1993-08-25 | Wyeth John & Brother Ltd | Heterocyclic derivatives |
US5609849A (en) * | 1994-03-11 | 1997-03-11 | The Trustees Of The University Of Pennsylvania | Serotonin (5-HT1A) receptor ligands and imaging agents |
CA2191874C (en) * | 1994-06-03 | 2008-05-20 | Christopher Ian Brightwell | Novel processes and intermediates for the preparation of piperazine derivatives |
GB9411099D0 (en) * | 1994-06-03 | 1994-07-27 | Wyeth John & Brother Ltd | Piperazine derivatives |
DE4425146A1 (en) * | 1994-07-15 | 1996-01-18 | Basf Ag | Use of heterocyclic compounds |
US6231833B1 (en) | 1999-08-05 | 2001-05-15 | Pfizer Inc | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors |
EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug response by a serotonin 1A receptor antagonist |
FR2727682A1 (en) * | 1994-12-02 | 1996-06-07 | Pf Medicament | NOVEL DERIVATIVES OF 3,5-DIOXO- (2H, 4H) -1,2,4-TRIAZINES, THEIR PREPARATION AND THEIR USE AS A MEDICINAL PRODUCT |
US5541179A (en) * | 1995-05-02 | 1996-07-30 | American Home Products Corporation | Tropon-2-one piperazine carboxamides as serotonergic agents |
GB9514901D0 (en) * | 1995-07-20 | 1995-09-20 | American Home Prod | Piperazine derivatives |
EP0759299B1 (en) * | 1995-08-16 | 2000-04-26 | Eli Lilly And Company | Potentiation of serotonin response |
GB9525239D0 (en) * | 1995-12-09 | 1996-02-07 | American Home Prod | Medical treatment |
IT1282705B1 (en) * | 1996-02-28 | 1998-03-31 | Recordati Chem Pharm | USE OF 5-HT | A SEROTONINERGIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE |
US5990114A (en) * | 1996-02-28 | 1999-11-23 | Recordati, S.A., Chemical And Pharmaceutical Company | Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence |
DE19615232A1 (en) * | 1996-04-18 | 1997-10-23 | Merck Patent Gmbh | New carbamoyl derivatives and their use as 5-HT ¶1¶¶A¶ antagonists |
FR2753968B1 (en) * | 1996-09-27 | 1998-11-27 | Sod Conseils Rech Applic | NOVEL HETEROARYLOXYETHYLAMINES, THEIR PREPARATION METHOD, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2756283A1 (en) * | 1996-11-27 | 1998-05-29 | Pf Medicament | ARY AMINES OF ARYLPIPERAZINES, THEIR PREPARATION AND THEIR APPLICATIONS AS MEDICAMENTS |
WO1998039301A1 (en) * | 1997-03-04 | 1998-09-11 | Neurogen Corporation | 1-(isoquinolin-1-yl)-4-(1-phenylmethyl)piperazines; dopamine receptor subtype specific ligands |
US6008352A (en) * | 1997-04-03 | 1999-12-28 | Neurogen Corporation | 1-(isoquinolin-1-yl)-4-(1-phenylmethyl) piperazines; dopamine receptor subtype specific ligands |
AU8296998A (en) * | 1997-06-13 | 1998-12-30 | Neurogen Corporation | 2-aminoalkylaminoquinolines as dopamine d4 ligands |
IT1293804B1 (en) | 1997-08-01 | 1999-03-10 | Recordati Chem Pharm | DIARYLALKYL PIPERAZINS ACTIVE ON LOW URINARY TRACT |
US6271234B1 (en) * | 1997-08-01 | 2001-08-07 | Recordati S.A., Chemical And Pharmaceutical Company | 1,4-disubstituted piperazines |
JP2001512110A (en) * | 1997-08-01 | 2001-08-21 | レコルダチ エッセ.ア.,ケミカル アンド ファーマシューティカル カンパニー | 1,4-disubstituted piperazine |
US6399614B1 (en) | 1997-08-01 | 2002-06-04 | Recordati S.A. Chemical And Pharmaceutical Company | 1-(N-phenylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring |
ATE253058T1 (en) | 1997-09-02 | 2003-11-15 | Duphar Int Res | PIPERIDINE AND PIPERAZINE DERIVATIVES AS 5-HT1 RECEPTOR AGONISTS |
EP0900792B1 (en) * | 1997-09-02 | 2003-10-29 | Duphar International Research B.V | Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists |
UA66370C2 (en) | 1997-12-16 | 2004-05-17 | Lilly Co Eli | Arylpiperazines having activity to setotonin 1 receptors |
US6281216B1 (en) | 1998-02-09 | 2001-08-28 | Duphar International Research B.V. | 2-aminoquinoline derivatives having d4-agonistic activity |
JP2002518382A (en) * | 1998-06-15 | 2002-06-25 | アメリカン・ホーム・プロダクツ・コーポレイション | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonin agonists |
US6344458B1 (en) | 1998-12-17 | 2002-02-05 | American Home Products Corporation | Piperazine ethylamide derivatives |
WO2000035892A1 (en) * | 1998-12-17 | 2000-06-22 | American Home Products Corporation | Piperazine ethylamide derivatives with 5-ht1a receptor activity |
KR100333500B1 (en) * | 2000-01-19 | 2002-04-25 | 박호군 | Arylpiperazine compounds and preparation method thereof |
US6613901B2 (en) | 2000-03-08 | 2003-09-02 | Neurogen Corporation | 2-aminoalkylaminoquinolines as dopamine D4 ligands |
US20060287335A1 (en) | 2000-11-28 | 2006-12-21 | Wyeth | Serotonergic agents for treating sexual dysfunction |
US6469007B2 (en) | 2000-11-28 | 2002-10-22 | Wyeth | Serotonergic agents |
US20060223824A1 (en) * | 2000-11-28 | 2006-10-05 | Wyeth | Serotonergic agents |
JP5080716B2 (en) | 2001-07-20 | 2012-11-21 | サイコジェニックス・インコーポレーテッド | Treatment of attention deficit / hyperactivity disorder |
AU2002326948A1 (en) * | 2001-09-18 | 2003-04-01 | Bristol-Myers Squibb Company | Piperizinones as modulators of chemokine receptor activity |
US7361773B2 (en) * | 2002-03-12 | 2008-04-22 | Wyeth | Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
AU2003220110B2 (en) * | 2002-03-12 | 2009-04-09 | Wyeth | Process for making chiral 1,4-disubstituted piperazines |
KR20040105765A (en) * | 2002-03-12 | 2004-12-16 | 와이어쓰 | Process for synthesizing chiral N-aryl piperazines |
US7091349B2 (en) | 2002-03-12 | 2006-08-15 | Wyeth | Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution |
ATE360002T1 (en) * | 2002-03-12 | 2007-05-15 | Wyeth Corp | METHOD FOR PRODUCING N1-(2'-PYRIDYL)-1,2-PROPANEDIAMINESULFAMID ACID AND USE THEREOF FOR PRODUCING BIOLOGICALLY ACTIVE PIPERAZINES |
WO2003099266A2 (en) * | 2002-05-23 | 2003-12-04 | Abbott Laboratories | Acetamides and benzamides that are useful in treating sexual dysfunction |
WO2004026864A1 (en) * | 2002-09-17 | 2004-04-01 | Warner-Lambert Company Llc | Heterocyclic substituted piperazines for the treatment of schizophrenia |
CA2505397A1 (en) * | 2002-11-08 | 2004-05-21 | Warner-Lambert Company Llc | Phenylalkyl and pyridylalkyl piperazine derivatives |
US7179813B2 (en) | 2003-06-11 | 2007-02-20 | Wyeth | Bicyclic indolyl derivatives and methods for their use as serotonergic agents |
US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
JP2007513197A (en) * | 2003-12-08 | 2007-05-24 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia |
US20050165025A1 (en) * | 2004-01-22 | 2005-07-28 | Recordati Ireland Ltd. | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists |
US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
US20070099931A1 (en) * | 2004-03-19 | 2007-05-03 | Wyeth | Pharmaceutical dosage forms and compositions |
PA8626301A1 (en) * | 2004-03-19 | 2006-12-07 | Wyeth Wyeth | PROCESS TO PREPARE DERIVATIVES OF N-ARIL-PIPERAZINA |
CN1964987A (en) * | 2004-06-04 | 2007-05-16 | 惠氏公司 | Inhibitors of REGIII proteins as asthma therapeutics |
EP1817269B1 (en) * | 2004-11-05 | 2013-01-02 | GE Healthcare Limited | Use of [11c] carbon monoxide in labeling synthesis of 11c-labelled amides using photo-induced free radical carbonylation |
JP2008531694A (en) * | 2005-03-01 | 2008-08-14 | ワイス | Crystalline and amorphous 4-cyano-N-{(2R) -2- [4- (2,3-dihydro-benzo [1,4] dioxin-5-yl) -piperazin-1-yl] -propyl } -N-pyridin-2-yl-benzamide hydrochloride |
WO2006103559A1 (en) * | 2005-04-01 | 2006-10-05 | Warner-Lambert Company Llc | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia |
TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
BRPI0611948A2 (en) * | 2005-06-17 | 2010-10-13 | Wyeth Corp | compounds useful as serotonin inhibitors and 5-ht1a antagonist agonists |
US7731940B2 (en) | 2006-01-25 | 2010-06-08 | The Regents Of The University Of California | Compositions and methods related to serotonin 5-HT1A receptors |
TW200811144A (en) * | 2006-06-09 | 2008-03-01 | Wyeth Corp | Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
TW200808741A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
US20080262228A1 (en) * | 2006-11-28 | 2008-10-23 | Wyeth | Metabolites of 5-fluoro-8- quinoline and methods of preparation and uses thereof |
CL2008000119A1 (en) * | 2007-01-16 | 2008-05-16 | Wyeth Corp | COMPOUNDS DERIVED FROM PIRAZOL, ANTAGONISTS OF THE NICOTINIC ACETILCOLINE RECEIVER; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS SENILE DEMENTIA, ALZHEIMER AND SCHIZOPHRENIA. |
WO2010137018A1 (en) | 2009-05-27 | 2010-12-02 | Atir Holding S.A. | Piperazine, piperidine and tetrahydropyridine derivatives and their pharmaceutical use |
DK2445502T4 (en) * | 2009-06-25 | 2022-11-28 | Alkermes Pharma Ireland Ltd | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS |
JP5732453B2 (en) | 2009-06-25 | 2015-06-10 | アルカーメス ファーマ アイルランド リミテッド | Prodrugs of NH acidic compounds |
CA2802733C (en) | 2010-06-24 | 2017-11-21 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
RU2757859C2 (en) | 2011-03-18 | 2021-10-21 | Алкермес Фарма Айэленд Лимитед | Pharmaceutical compositions containing water-insoluble antipsychotic drug and sorbitan esters |
GB201112987D0 (en) * | 2011-07-28 | 2011-09-14 | Ge Healthcare Ltd | Novel compound |
US8969337B2 (en) | 2011-12-15 | 2015-03-03 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
US10004807B2 (en) | 2012-03-19 | 2018-06-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
US9993556B2 (en) | 2012-03-19 | 2018-06-12 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty glycerol esters |
WO2013142205A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
US9193685B2 (en) | 2012-09-19 | 2015-11-24 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
CN103864761B (en) * | 2014-03-12 | 2016-01-20 | 天津药物研究院有限公司 | A kind of piperazine derivative containing pyridine and its production and use |
EP3119399A4 (en) | 2014-03-20 | 2017-09-27 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
KR101556571B1 (en) | 2014-03-31 | 2015-10-01 | (주)월드트렌드 | Spectacle frame for locking ornament jewelry |
CN107205970A (en) | 2014-11-05 | 2017-09-26 | 弗莱塞斯生物科学公司 | Immunomodulator |
UY36390A (en) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
MA41168A (en) * | 2014-12-17 | 2017-10-24 | Acraf | NEW ANTIBACTERIAL COMPOUNDS |
DK3468975T3 (en) * | 2016-06-08 | 2020-07-13 | Acraf | NEW ANTIBACTERIAL COMPOUNDS |
WO2019173230A1 (en) | 2018-03-05 | 2019-09-12 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
KR20210076226A (en) | 2019-12-13 | 2021-06-24 | 주식회사 에피바이오텍 | A composition for prevention or treatment of hair loss comprising piperazine deravitives |
WO2023144764A1 (en) | 2022-01-29 | 2023-08-03 | Suven Life Sciences Limited | Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders |
CN117003693A (en) * | 2022-05-05 | 2023-11-07 | 四川大学华西医院 | Piperidine derivatives, preparation method and application thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1279843A (en) * | 1969-05-23 | 1972-06-28 | Science Union & Cie | Benzamidoethyl-piperazines and process for their preparation |
US4684651A (en) * | 1981-03-17 | 1987-08-04 | Mitsubishi Chemical Industries Limited | Alkylenedioxybenzene and acid addition salts thereof useful as hypotensives |
JPS58154573A (en) * | 1982-03-09 | 1983-09-14 | Mitsubishi Chem Ind Ltd | Alkylenedioxybenzene derivative and its acid adduct salt |
JPS5910517A (en) * | 1982-07-09 | 1984-01-20 | Mitsubishi Chem Ind Ltd | Hypotensor |
AR241161A1 (en) * | 1984-07-30 | 1991-12-30 | Merrelll Dow Pharmaceuticals I | "PROCEDURE FOR THE PREPARATION OF SUBSTITUTED N-AMINOALKYLEN DERIVATIVES OF GLUTARIMIDE" |
US5010078A (en) * | 1988-05-24 | 1991-04-23 | American Home Products Corporation | Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity |
EP0367888A1 (en) * | 1988-11-08 | 1990-05-16 | ISTITUTO LUSO FARMACO D'ITALIA S.p.A. | 2,2-Disubstituted 2,3-dihydro-1,4-benzodioxin derivatives having hypotensive activity |
NZ231631A (en) * | 1988-12-08 | 1992-07-28 | Duphar Int Res | Heterocyclically-substituted piperazine and diazepine derivatives and anxiolytic compositions |
GB8909209D0 (en) * | 1989-04-22 | 1989-06-07 | Wyeth John & Brother Ltd | Piperazine derivatives |
US5112824A (en) * | 1989-12-08 | 1992-05-12 | Merck & Co., Inc. | Benzofuran compounds as class III antiarrhythmic agents |
IE911774A1 (en) * | 1990-06-11 | 1991-12-18 | Akzo Nv | Pyridinylpiperazine derivatives |
AU645681B2 (en) * | 1991-05-02 | 1994-01-20 | John Wyeth & Brother Limited | Piperazine derivatives |
GB9411099D0 (en) * | 1994-06-03 | 1994-07-27 | Wyeth John & Brother Ltd | Piperazine derivatives |
-
1992
- 1992-04-29 AU AU15241/92A patent/AU645681B2/en not_active Ceased
- 1992-04-29 MX MX9201991A patent/MX9201991A/en active IP Right Grant
- 1992-04-29 IL IL10172292A patent/IL101722A/en active IP Right Grant
- 1992-04-30 HU HU9201462A patent/HU223527B1/en not_active IP Right Cessation
- 1992-04-30 FI FI921942A patent/FI108720B/en active
- 1992-04-30 BR BR929201624A patent/BR9201624A/en not_active Application Discontinuation
- 1992-04-30 ES ES92303918T patent/ES2065133T3/en not_active Expired - Lifetime
- 1992-04-30 MY MYPI92000746A patent/MY107756A/en unknown
- 1992-04-30 DE DE69200893T patent/DE69200893T2/en not_active Expired - Lifetime
- 1992-04-30 GB GB9209340A patent/GB2255337B/en not_active Expired - Fee Related
- 1992-04-30 RU SU5011552/04A patent/RU2193561C2/en active
- 1992-04-30 AT AT92303918T patent/ATE115566T1/en not_active IP Right Cessation
- 1992-04-30 EP EP92303918A patent/EP0512755B1/en not_active Expired - Lifetime
- 1992-04-30 DK DK92303918.4T patent/DK0512755T3/en active
- 1992-05-01 JP JP04112527A patent/JP3095521B2/en not_active Expired - Fee Related
- 1992-05-01 CA CA002067929A patent/CA2067929C/en not_active Expired - Lifetime
- 1992-05-02 CN CN92103153A patent/CN1040106C/en not_active Expired - Fee Related
- 1992-05-02 KR KR1019920007528A patent/KR100203254B1/en not_active IP Right Cessation
- 1992-05-04 SK SK1344-92A patent/SK280133B6/en not_active IP Right Cessation
- 1992-05-04 CZ CS19921344A patent/CZ286778B6/en not_active IP Right Cessation
- 1992-07-01 IE IE921409A patent/IE64634B1/en not_active IP Right Cessation
-
1993
- 1993-06-15 UA UA93002895A patent/UA39917C2/en unknown
-
1995
- 1995-05-11 US US08/438,812 patent/US6127357A/en not_active Expired - Fee Related
- 1995-06-22 HU HU95P/P00338P patent/HU211148A9/en unknown
-
1996
- 1996-12-06 CN CN96118586A patent/CN1084619C/en not_active Expired - Fee Related
-
1998
- 1998-03-12 HK HK98102076A patent/HK1003001A1/en not_active IP Right Cessation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972945A (en) * | 1997-06-13 | 1999-10-26 | Neurogen Corporation | 2-aminoalkylaminoquinolines; dopamine receptor subtype specific ligands |
US6313141B1 (en) | 1997-06-13 | 2001-11-06 | Neurogen Corporation | 2-aminoalkylaminoquinolines as dopamine D4 ligands |
US7049330B2 (en) | 1998-06-15 | 2006-05-23 | Wyeth | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
US6828324B2 (en) | 1999-11-12 | 2004-12-07 | Wyeth | Branched adamantyl and noradamantyl aryl-and aralkylpiperazines with serotonin 5-HT1A activity |
US6831084B1 (en) | 1999-11-12 | 2004-12-14 | Wyeth | Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-HT1A activity |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0512755B1 (en) | Piperazine derivatives | |
US5532242A (en) | Piperazine derivatives as 5-HT receptors antagonists | |
SK281418B6 (en) | Piperazine derivatives, processes and intermediates for their preparation, their use as 5-ht1a antagonists and pharmaceutical compositions based thereon | |
US5622951A (en) | Piperazine derivatives as 5-HT antagonists | |
EP1656351B1 (en) | Process for preparation of 4-aryl-nicotinamide derivatives | |
IL94160A (en) | 1,4-Disubstituted piperazines | |
US5430033A (en) | Piperazine derivatives | |
EP0690845B1 (en) | Piperazine derivatives as 5-ht1a ligands | |
US5629323A (en) | Amide derivatives as 5-HT1A ligands | |
EP0481742B1 (en) | Piperazine derivatives | |
CA2199889A1 (en) | Use of naphthalene derivatives in treating lung carcinoma | |
EP0687257B1 (en) | 4-amino-2-(hetero)aryl-butanamides useful as 5-ht1a-antagonists | |
CA2293480A1 (en) | 2-aminoalkylaminoquinolines as dopamine d4 ligands | |
Cliffe et al. | Piperazine derivatives as 5-HT 1A ligands | |
Cliffe et al. | Amide derivatives as 5-HT 1A ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GR IT LI LU NL PT SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GR IT LI LU NL PT SE |
|
17P | Request for examination filed |
Effective date: 19930612 |
|
17Q | First examination report despatched |
Effective date: 19930906 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
ITF | It: translation for a ep patent filed |
Owner name: BARZANO' E ZANARDO MILANO S.P.A. |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GR IT LI LU NL PT SE |
|
REF | Corresponds to: |
Ref document number: 115566 Country of ref document: AT Date of ref document: 19941215 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 69200893 Country of ref document: DE Date of ref document: 19950126 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2065133 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3014376 |
|
ET | Fr: translation filed | ||
SC4A | Pt: translation is available |
Free format text: 941220 AVAILABILITY OF NATIONAL TRANSLATION |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: JOHN WYETH & BROTHER LIMITED Free format text: JOHN WYETH & BROTHER LIMITED#HUNTERCOMBE LANE SOUTH TAPLOW#MAIDENHEAD/BERKS (GB) -TRANSFER TO- JOHN WYETH & BROTHER LIMITED#HUNTERCOMBE LANE SOUTH TAPLOW#MAIDENHEAD/BERKS (GB) |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20080318 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20080507 Year of fee payment: 17 Ref country code: PT Payment date: 20080414 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20090313 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20080411 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20090420 Year of fee payment: 18 Ref country code: SE Payment date: 20090406 Year of fee payment: 18 Ref country code: NL Payment date: 20090409 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20090430 Year of fee payment: 18 |
|
BERE | Be: lapsed |
Owner name: JOHN *WYETH & BROTHER LTD Effective date: 20090430 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20091102 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091102 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091104 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20100420 Year of fee payment: 19 Ref country code: FR Payment date: 20100420 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20100424 Year of fee payment: 19 Ref country code: DE Payment date: 20100430 Year of fee payment: 19 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20101101 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101101 |
|
EUG | Se: european patent has lapsed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100430 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100501 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100503 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20111230 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111101 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110502 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69200893 Country of ref document: DE Effective date: 20111101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110430 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20120604 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110501 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100430 |